Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07135804 | Sep 2025 → Apr 2028 expected | nasopharyngeal squamous cell carcinoma | Second Affiliated Hospital of Nanchang University | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07135804 ↗ |